Effect of hepatitis C virus on C-reactive protein and interleukin-6 in hemodialysis patients

Iranian Journal of Kidney Diseases

Volumn 5, Issue 3, 2011, Pages 182-186

  Afzal, Nadeem ^a   Abbas, Sarwar ^a   Ahmed, Azazmand ^b   Arif, Maria ^a   Javeed, Khursheed ^a  

^a UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b Sheikh Zayed Hospital   (Pakistan)

Author keywords

C reactive protein; End stage renal disease; Hepatitis C virus; Interleukin 6; Renal dialysis

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; BIOLOGICAL MARKER; HEPATITIS C ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY FAILURE; MAINTENANCE THERAPY; MALE; PROTEIN BLOOD LEVEL; TREATMENT DURATION; BLOOD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DISEASE TRANSMISSION; FOLLOW UP; IMMUNOLOGY; INCIDENCE; IRAN; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RISK FACTOR; VIROLOGY;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INCIDENCE; INTERLEUKIN-6; IRAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK FACTORS; YOUNG ADULT;

EID: 79956321291     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Almawi Y, Qadi A, Tamim H, Ameen G, Bu-Ali A, Abou J. Seroprevalnce of hepatitis C and B among dialysis patients in Bahrain and Saudi Arabia. Transplant Proc. 2004;36:1824-26.
2. Baid-Agrawal S, Pascual M, Moradpour D, Frei U, Tolkoff-Rubin N. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol. 2008;18:97-115.
3. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36:3-10.
4. Nascimento MM, Bruchfeld A, Suliman ME, et al. Effect of hepatitis C serology on C-reactive protein in a cohort of Brazilian hemodialysis patients. Braz J Med Biol Res. 2005;38:783-8.
5. Amiri ZM, Shakib AJ, Toorchi M. Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Islamic Republic of Iran. East Mediterr Health J. 2005;11:372-6.
6. Ocak S, Duran N, Kaya H, Emir I. Seroprevalence of hepatitis C in patients with type 2 diabetes mellitus and non-diabetic on haemodialysis. Int J Clin Pract. 2006;60:670-4.
7. Bdour S. Hepatitis C virus infection in Jordanian haemodialysis units: serological diagnosis and genotyping. J Med Microbiol. 2002;51:700-4.
8. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000;11:1896-902.
9. Kalantar-Zadeh K, McAllister CJ, Miller LG. Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study. Nephrol Dial Transplant. 2005;20:1662-9.
10. Borazan A, Ustun H, Ustundag Y, et al. The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels. Mediators Inflamm. 2004;13:201-4.
11. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119:172-80.
12. Oda T. Viral hepatitis and hepatocellular carcinoma prevention strategy in Japan. Jpn J Cancer Res. 1999;90:1051-60.
13. Malik IA, Tarq WZ. The prevalence and pattern of viral hepatitis in Pakistan. J Coll Physicians Surg Pak. 1995;5:2-3.
14. Karamat AK. Viral hepatitis: An over view. Proceeding of the seminar AFIP Rawalpindi, Pakistan: 1998; p. 16-7.
15. Varley H. Practical biochemistry. 6th ed. New Delhi: CBS Publishers; 2006. p. 426.
16. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol. 2007;18:1584-93.
17. Panichi V, Migliori M, De Pietro S, et al. C reactive protein in patients with chronic renal diseases. Ren Fail. 2001;23:551-62.
18. Stenvinkel P, Lindholm B. C-reactive protein in end-stage renal disease: are there reasons to measure it? Blood Purif. 2005;23:72-8.
19. Wang AY. Prognostic value of C-reactive protein for heart disease in dialysis patient. Curr Opin Investig Drugs. 2005;6:879-86
20. Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton). 2006;11:36-41.
21. Dupuy AM, Terrier N, Senecal L, et al. [Is C-reactive protein a marker of inflammation?]. Nephrologie. 2003;24: 337-41. French.
22. Amezcua-Guerra LM, Springall del Villar R, Bojalil Parra R. [C-reactive protein: cardiovascular issues of an acute-phase protein]. Arch Cardiol Mex. 2007;77: 58-66. Spanish.
23. Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant. 1999;14:1956-60.
24. Thompson ME, Barkhuizen A. Fibromyalgia, hepatitis C infection, and the cytokine connection. Curr Pain Headache Rep. 2003;7:342-7.
25. Content J, De Wit L, Pierard D, Derynck R, De Clercq E, Fiers W. Secretory proteins induced in human fibroblasts under conditions used for the production of interferon beta. Proc Natl Acad Sci U S A. 1982;79:2768-72.
26. Loppnow H, Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest. 1990;85:731-8.
27. Rao CV. Immunology: a textbook. Oxford, UK: Alpha Science International; 2006. p. 220.
28. Kaysen GA. Inflammation: cause of vascular disease and malnutrition in dialysis patients. Semin Nephrol. 2004;24:431-6.
29. Zoccali C, Tripepi G, Mallamaci F. Predictors of cardiovascular death in ESRD. Semin Nephrol. 2005;25:358-62.
30. Einollahi B, Alavian SM. Hepatitis C virus infection and kidney transplantation: a review for clinicians. Iran J Kidney Dis. 2010; 4:1-8.
31. Penne EL, van der Weerd NC, Grooteman MP, Blankestijn PJ. Results from the RISCAVID study: is haemodiafiltration associated with improved survival? Nephrol Dial Transplant. 2008;23:3034.
32. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648-58.
33. Taskapan MC, Taskapan H, Sahin I, Keskin L, Atmaca H, Ozyalin F. Serum leptin, resistin, and lipid levels in patients with end stage renal failure with regard to dialysis modality. Ren Fail. 2007;29:147-54.
34. Panichi V, Migliori M, De Pietro S. Plasma C-reactive protein in hemodialysis patients: a cross-sectional, longitudinal clinical survey. Blood Purif. 2000; 18:30-6.
35. Park CW, Shin YS, Kim CM, et al. Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am J Kidney Dis. 2002;40:1230-9.
36. Razeghi E, Omati H, Maziar S, Khashayar P, Mahdavi-Mazdeh M. Chronic inflammation increases risk in hemodialysis patients. Saudi J Kidney Dis Transpl. 2008;19:785-9.
37. Hung A, Pupim L, Yu C, et al. Determinants of C-reactive protein in chronic hemodialysis patients: relevance of dialysis catheter utilization. Hemodial Int. 2008;12:236-43.
38. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int. 1991;39:954-60.
39. Beharka AA, Meydani M, Wu D, Leka LS, Meydani A, Meydani SN. Interleukin-6 production does not increase with age. J Gerontol A Biol Sci Med Sci. 2001;56:B81-8.
40. Rao M, Guo D, Perianayagam MC, et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2005;45:324-33.
41. Zumrutdal A, Ozer B, Singan M, et al. Effect of anti-HCV positivity on markers of malnutrition and inflammation in hemodialysis patients. Ren Fail. 2007;29:85-90.
42. Kaizu Y, Kimura M, Yoneyama T, Miyaji K, Hibi I, Kumagai H. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis. 1998;31:93-100.